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Peripheral Blood Lymphocyte Activation and RANTES
Levels in Asthma
Aim: Bronchial mucosal inflammation is one of the major characteristics of atopic asthma. Th2 activation and
the related cytokine profile, eosinophil activation and infiltration play the main role in the pathogenesis of
atopic asthma. The aim of this study was to demonstrate the activation and RANTES (regulated on activation,
normal T-cell expressed and presumably secreted) expression of peripheral blood lymphocytes of non-atopic
and atopic asthmatic patients.
Materials and Methods: CD3, CD4, CD8, CD16, CD23, CD25, CD45RA and CD45RO expressions were
determined in 22 asthma patients and 20 healthy control subjects by flow cytometry, and RANTES levels were
measured by ELISA. Statistical analysis was performed by using Student’s t and Mann-Whitney U test.
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Results: CD45RO and CD23 expressions were significantly higher in asthma patients compared to control
subjects (P = 0.009 and P = 0.004, respectively), and similarly, an increase in CD25 expression was also
shown in asthmatics (P = 0.004). However, there was no difference in RANTES secretion of peripheral blood
lymphocytes in asthmatics compared to the control group (P = 0.08). Atopic and non-atopic asthmatics
(13 vs. 9) were compared, and atopic asthmatics showed significant increase in CD25 and CD23 expressions
(P = 0.009 and P = 0.02, respectively).
Conclusions: These changes in the activation state of T-cells suggest an active role of T lymphocytes in the
pathogenesis of atopic and non-atopic asthma.
Key Words: Asthma, lymphocyte activation, RANTES

Astımda Periferik Lenfosit Aktivasyonu ve RANTES Düzeyleri
Amaç: Bronşiyal mukozal inflamasyon atopik astımın en temel özelliklerinden biridir. Th2 aktivasyonu ve buna
bağlı sitokin profili, eozinofil aktivasyonu ve infiltrasyonu atopik astımın patogenezinde önemli rol almaktadır.
Bu çalışmada amaç non-atopik ve atopik astmatik olgularda periferik kan lenfositlerinde aktivasyonu ve
RANTES (normal T hücrede eksprese ve sekrete edilen, aktivasyonla düzenlenen) ekspresyonunu ortaya
koymaktır.
Yöntem ve Gereç: CD3, CD4, CD8, CD16, CD23, CD25, CD45RA ve CD45RO ekspresyonları 22 astım
hastası ve 20 sağlıklı kontrol olgusunda flow sitometri ile; RANTES düzeyleri ise ELISA ile saptanmıştır.
İstatistiksel analizde Student’s t testi ve Mann Whitney U testi kullanılmıştır.
Bulgular: CD45RO ve CD23 ekspresyonları astımlı olgularda sağlıklı bireylere göre anlamlı olarak yüksek
bulunmuştur (P = 0.009 ve P = 0.004, sırasıyla), benzer şekilde CD25 ekspresyonu da astımda yükselmiştir
(P = 0.004). Buna karşılık periferik lenfosit RANTES salınımında astmatik olgular ve sağlıklı bireyler arasında
fark saptanmamıştır (P = 0.08). Atopik ve non-atopik astımlı hastalar (13/9) karşılaştırıldığında; atopik
astımda CD25 ve CD23 ekspresyonları anlamlı düzeyde yüksek bulunmuştur (P = 0.009 ve P = 0.02,
sırasıyla).
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Sonuç: T hücrelerinin aktivasyon durumundaki değişiklikler bu hücrelerin atopik ve non-atopik astım
patogenezindeki rolünü işaret etmektedir.
Anahtar Sözcükler: Astım, lenfosit aktivasyonu, RANTES
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Introduction
Asthma is a chronic inflammatory disease characterized by increased responsiveness
of the tracheobronchial tree to a variety of stimuli. Clinically, asthma can be subdivided
into the variants as extrinsic and intrinsic asthma. Extrinsic asthma is also known as
allergic, or atopic, and generally develops in childhood, and family history is common.
Intrinsic asthma, however, known as nonallergic or non-atopic, develops after upper
respiratory tract infections, occurs unrelated to pollen seasons and skin tests are negative
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(1). In atopic asthma, allergen-specific IgE bound to mast
cell via Fc receptor plays a role in the activation of the
mast cell causing the release of the granule contents
(histamine, tumor necrosis factor [TNF]-α, proteases),
synthesis of a variety of lipid membrane-derived molecules
(heparin, LTC4, LTB4, PGD2, PAF) and the production of
a number of cytokines (interleukin [IL]-1, IL-3, IL-4, IL-5,
IL-6, IL-8, TNF-α granulocyte- macrophage colonystimulating factor [GM-CSF] and macrophage
inflammatory protein [MIP]-1α) (2). The result is
vasodilatation, increased vasopermeability and increased
endothelial adhesiveness to leukocytes. The inflammatory
cells, like eosinophils, basophils, macrophages and
lymphocytes, reach the lung and release their own
mediators causing bronchoconstriction, mast cell
multiplication, mucus secretion and tissue damage. Th2
lymphocyte activation has been shown to play the key role
in the inflammatory response in asthmatic airways. This
can be shown by increased numbers of CD25 (IL-2Rα) of
T-cells and by IL-4-mediated B-cell expression of CD23
(IgE receptor low affinity) (3). The Th2 hypothesis of
allergy considers atopy as a Th2-driven hypersensitivity
reaction driven by IL-4, IL-5 and IL-13 (4). Chemokines
stimulating chemokinesis and chemotaxis also play a role
in allergy and asthma. Chemokines of the beta subfamily
do stimulate human eosinophils and basophils and are
considered to be mediators of inflammation. RANTES
(regulated on activation, normal T-cell expressed and
presumably secreted), a CC chemokine, can be released
from activated macrophages and is a potent
chemoattractant for eosinophils, monocytes and T-cells
(5), and acts in acute inflammatory responses (6). A
report by the Manchester group showed an interesting
link between RANTES polymorphisms and asthma. Their
report shows that the rare variant of the RANTES gene is
associated with high risk of asthma and severe airway
obstruction (7). In this study, lymphocyte activation and
related RANTES levels were investigated in atopic and
non-atopic asthma.

study were mild non-smoker asthmatics under inhaled
corticosteroid (ICS) ± long-acting beta agonist (LABA)
therapy. Their asthma symptoms had been under control
for at least one month.
The study protocol was approved by the Ethical Board
of the Istanbul Faculty of Medicine.
Cell Purification
Peripheral blood mononuclear cells (PBMC) were
obtained from heparinized blood by density gradient
centrifugation over Ficoll (Sigma Chemical Company, St.
Louis, MO, USA), and washed twice by phosphate
buffered saline (PBS) (pH 7.4). The cells were stained
with PE- or FITC-conjugated isotype control antibodies
(Abs) (rat IgG1 and rat IgG2a), anti-human CD4FITC/CD8-PE (Caltag, Burlingame, CA, USA), anti-human
CD3-FITC/CD19-PE (Ancell, Bayport, MN, USA), antihuman CD16-FITC (DAKO, Carpinteria, CA, USA), antihuman CD45RO-PE (Pharmingen, San Diego, CA, USA),
anti-human CD45RA-FITC (Pharmingen, San Diego, CA,
USA), anti-human CD25-FITC (Pharmingen, San Diego,
CA, USA), anti-human CD23-PE (Pharmingen, San Diego,
CA, USA) for 30 min at 4oC and analyzed by flow
cytometry (Epics Profile II, Coulter, USA).
Quantitation of RANTES
The solid phase sandwich ELISA for RANTES was
performed by ELISA (Endogen, Cambridge, MA, USA).
The sensitivity of RANTES ELISA was <2 pg/ml.
Statistical Evaluation
Data are expressed as means ± SEM. Statistical
analyses for comparisons were performed by Student’s t
and Mann-Whitney U test.
Table. Characteristics of the asthmatic subjects.

Number of subjects
Sex (male/female)
Mean age

Materials and Methods
Study Population
Twenty-two asthmatic patients (mean age 36 ± 8)
and 20 healthy control subjects (mean age 38 ± 12) were
enrolled in this study (8). Characteristics of the patients
are shown in Table . All the patients participating in this
532
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Asthma duration (year)
ICS usage (N)

Atopic

Non-atopic

Control

13

9

20

4/9

2/7

10/10

35.2 ± 12.8

38.8 ± 12.7

36.3 ± 8.5

9.6 ± 4.1

10.3 ± 5.2

-

13

9

-

LABA usage (N)

3

2

-

FEV1 (% PRED)

87 ± 13.6

86 ± 18.5

92.2 ± 8.4

ICS: inhaled corticosteroid; LABA: long-acting beta agonists;
FEV1: forced expiratory volume in one second.
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Results
Antigen Expression
Surface expressions of the low affinity IgE receptor
CD23 and memory T-cell marker CD45RO were
increased in the peripheral blood of all asthmatics
compared to healthy subjects (P = 0.004 and P =
0.009, respectively, Figure 1), but there was no
difference in CD3 expressed on T-cells or in CD4 on class
II MHC restricted T-cells in asthmatic and control groups
(data not shown). Expressions of CD8, MHC class I
restricted T-cell marker; CD16, NK marker; CD19,
expressed on most B–cells; and CD45RA, expressed on
naive T–cells, did not show any difference between
asthmatic and healthy individuals (data not shown).
However, an increase was determined in IL-2R
expressed on activated T- and B-cells, marked as CD25,
in the asthmatic group compared to healthy subjects

(P = 0.004, Figure 1). When differentiating the
asthmatic group into skin test-positive (n:13) and negative (n:9) subjects (to divide the asthmatic group
into atopic and non-atopic), skin test-positive asthmatics
showed a significant increase in CD25 and CD23
expression compared to skin test-negative subjects (P =
0.009 and P = 0.02, respectively, Figure 2). CD4/CD8
ratios did not show any difference in control and
asthmatic groups (2.00 ± 0.89 vs 1.90 ± 0.21).
RANTES Levels
Although an increase was shown in chemokine
RANTES determined by ELISA in the asthmatic group
compared to healthy individuals, this increase was not
statistically significant. RANTES levels of skin test-positive
and skin test-negative asthmatic patients also did not
show any difference (812.42 ± 219.89 pg/ml vs 851.33
± 292.95 pg/ml) (Figure 3).
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Figure 1. Expression of CD23, CD25 and CD45RO in asthmatic and
control subjects.

 

Figure 2. CD23, CD25 expressions in skin test-positive (atopic) and negative (non-atopic) asthmatic subjects.
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Figure 3. Serum RANTES levels in asthmatic and control subjects.
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Discussion
The role of inflammation in the pathogenesis of
asthma has been well described (9). Initial studies of
circulating T lymphocytes have suggested an increased
activation of these cells during exacerbations of asthma
(10). Extending the investigation of cell activity to the
airways, a study comparing T lymphocyte cell surface
activation markers, IL-2 receptor (IL-2R, CD25+) and the
class II major histocompatibility antigen, HLA-DR, in
peripheral blood and bronchoalveolar lavage (BAL) in mild
to moderately severe asthmatics and healthy control
subjects has shown a small but significant increase in the
state of activation of CD3+ T lymphocytes in asthma,
which was restricted to BAL cells (11). The lack of a
significant difference in CD3 levels in asthmatics
compared to controls in this study was thought to be due
to the patients being mild asthmatics.
The large majority of lymphocytes in the airway
mucosa are T-cells, which are likely to play a central role
in regulating inflammatory responses in the airways.
Examination of T-cell subsets has generally demonstrated
a predominance of CD4± cells over CD8±
(suppressor/cytotoxic) cells (12). Following antigen
challenge, changes in the T-cell subpopulation in the
airway sampled by BAL occur as early as 10 minutes after
instillation. Gratziou et al. (13) demonstrated lost
lymphocytes from the airway of asthmatics 10 minutes
following segmental challenge. These lost cells were
predominantly of the CD4 phenotype but fewer CD8 cells
were recovered as well. Moreover CD4/CD8 ratio fell
significantly over this short time period. Marked
variability in the CD4:CD8 ratio occurs; however, no
consistent alterations in the ratio of these T-cell subsets
have been reported in asthma (12). In contrast, no
significant difference in peripheral blood CD4/CD8 levels
was found. CD23 has been found at increased levels in
asthmatic and atopic individuals in previous studies and
has been implicated in other diseases characterized by
chronic inflammation (14,15). Similar to these findings,
our results showed significantly high CD23 expression in
asthmatics compared to healthy individuals and atopic
asthmatics compared to non-atopics. Several functional
roles for CD23 have been described, including T-celldependent IgE production, augmentation of B-cell
proliferation, enhancement of antigen presentation, and
mediation of T- and B-cell cognate interactions (16).
CD23 has also been linked to receptor-ligand interactions
534
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between T- and B-cells with effects on the CD40-CD40L
pathway and the β2-integrins (17). It is believed that
CD23 negatively regulates pulmonary inflammation and
airway hyperreactivity (18).
Another parameter for evaluating Th2 lymphocyte
activation is determination of CD25 expression of T
helper cells. A study performed by Hallstrand and
coworkers (3), demonstrated that the number of CD23bearing B-cells and the number of CD25-bearing T-cells
were increased in asthma compared to controls. With the
development of exercise-induced bronchospasm, there
was a significantly greater increase in CD23-positive Bcells and CD25-positive B-cells in the asthma group.
Similarly higher expressions of C23 and CD25 were also
found in asthmatic patients.
The CD45 surface marker is found on all leukocytes.
Several structural variants of this molecule have been
described (19). Consistent with T-cell populations in
other mucosal tissues, most T-cells in the airways carry
CD45RO surface marker associated with memory Tcells. This surface phenotype identifies T-cells that have
undergone prior activation by antigen (12). Several
studies have reported increased T-cells, number of
lymphocytes, or CD45RO+ cells in asthmatics compared
to healthy controls, but other studies have failed to
demonstrate any increase (20) in CD25 expression
(identifying IL-2R) on T-cells compared to normal and
atopic, non-atopic controls. Increased CD25 expression
was associated with EG2 (a secreted form of eosinophil
cationic protein [ECP]) staining of eosinophils, implying
a role of T-cells in the eosinophilic infiltrate in asthma
(21). Eosinophils extravasating into inflamed tissues
respond to chemotactic gradients and migrate toward
epithelial cells. Production of chemokines by epithelial
cells attracts critical inflammatory effector cells.
RANTES is one of these chemokines that cause
eosinophil chemotaxis (22). RANTES might be released
from various cells including lymphocytes and activated
platelets, and is considered to play an important role in
immune and allergic disorders. Recent studies
demonstrated the beneficial effects of topical steroids on
airway inflammation in asthma by reducing RANTESinduced leukocyte infiltration into the airway wall (23).
The findings suggest that certain antihistamines may act
as down-modulators of allergic inflammation, possibly
through a negative regulation of the chemokines
involved in activation and attraction of eosinophils (24).
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Many studies have also made an interesting link between
RANTES polymorphisms and asthma, showing that the
variant in the promoter region is associated with high
risk of asthma and severe airway obstruction (25). In
the patients with asthma, the plasma RANTES levels
were found to be elevated during acute attack and the
stable period compared to controls (26). In the present
study, although higher levels of RANTES were found in
asthmatics compared to controls, the difference did not
reach statistical significance. That finding may be the
result of ICS usage, which was shown to repress

RANTES by inhibition
transcription (27).
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NF-kappaB-dependent

In conclusion, these data suggest that activation of T
lymphocytes may be an event in the development of
airway inflammation. Although this T-cell-mediated
inflammation is more prominent in atopic asthmatics,
non-atopic asthmatics also show signs of inflammation in
the peripheral blood. RANTES secretion was not
associated with this T-cell activation in our patients with
mild stable asthma.
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